MoonLake Immunotherapeutics heads into the week with a sharp contradiction at its core: options traders are the most bullish they have been all year, while the founders and CFO have been selling stock steadily into the same rally that drove shares up 12% on the week.
The options signal is striking. The put/call ratio collapsed to 0.11 — nearly three standard deviations below its 20-day average of 0.16, and essentially at its 52-week low of 0.11. That is the most call-heavy positioning seen in the past year, reflecting aggressive demand for upside exposure. The catalyst appears to be Sunday's event, flagged in the earnings history: a June 22 announcement drove a 10.5% single-day gain, the strongest one-day reaction in the recent record. Borrow conditions offer no friction to that enthusiasm — availability is extremely loose at 674%, meaning shares to borrow are plentiful relative to what is already shorted. Cost to borrow has also halved over the week to under 0.5%, reinforcing that there is no short squeeze pressure animating the move.
Short interest tells a broadly relaxed story. Bears hold 7.9% of the free float — meaningful for a clinical-stage biotech but down 11% over the past month as shorts have trimmed. The ORTEX short score eased to 59.7 from a peak of 70.4 on June 19, suggesting the short-side intensity that briefly spiked earlier in the week has already partially unwound. The lending market is consistent with that: availability is near its most comfortable level of the past six weeks, with no sign of borrow tightening.
The insider picture cuts against the bullish options read. The Founder and Chief Scientific Officer, Kristian Reich, sold 150,000 shares across three consecutive days (June 15–17) for roughly $2.85 million in aggregate. The CFO, Matthias Bodenstedt, added further sales on June 17–18 and again on June 22 — the day after the catalyst event — offloading around $1.2 million in that cluster alone. These are not trivial amounts for a company of this size. The 90-day net insider figure looks large in aggregate partly due to share issuance mechanics, but the directional signal from the two most senior insiders is unambiguously one-sided: they have been selling into strength, not buying the dip.
The Street remains constructive but is not unanimously so. Analysts who cover the name lean bullish — BTIG and HC Wainwright reiterated Buy ratings earlier this month, and Needham raised its target to $30 from $25 in May. Price targets cluster in the $24–$45 range, implying meaningful upside from the current $21.22 close. One outlier stands out: RBC Capital carries a Sector Perform with a $13 target — well below where the stock trades — reflecting the bear case that commercialisation risk and competition from established IL-17 inhibitors remain unresolved. The bull case rests on Phase 3 data from sonelokimab expected mid-2026 and in Q4, with cash runway flagged to year-end 2027. The stock's EPS momentum factor ranks in the 24th percentile and the short score rank sits at 23rd — both modest — but the days-to-cover rank at the 68th percentile suggests shorts would take time to unwind if sentiment shifted hard.
Correlated peers had a broadly positive week: GLUE rose 14%, CGON gained 10%, and SPRY added 5%, so the MLTX move was part of a wider small-cap biotech bid rather than a company-specific re-rating. The next formal earnings event is August 5 — but the more immediate watchpoint is any Phase 3 data release for sonelokimab, which is the binary that options traders appear to be positioning around with unusual conviction.
See the live data behind this article on ORTEX.
Open MLTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
